Cytokines in the treatment of metastatic renal cell carcinoma (MRCC): intravenous interleukin and subcutaneous interferon-alpha versus subcutaneous interleukin and interferon-alpha for good prognosis patients [PERCY DUO]
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2012
At a glance
- Drugs Interferon alpha; Interleukin-2; Interleukin-2
- Indications Renal cancer
- Focus Therapeutic Use
- 15 Sep 2008 Primary endpoint 'overall survival' has not been met.
- 15 Sep 2008 Results published in Clinical Cancer Research.
- 01 Feb 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History